Survey shows low faith in Lilly, Pfizer Alzheimer’s drugs

<p>(Reuters) – Institutional investors doubt that treatments for Alzheimer’s illness being grown by <span>Pfizer Inc</span> and <span>Eli Lilly</span> will grasp a categorical goals of their ongoing late-stage trials, though hopes are using distant aloft for a <span>Pfizer drug</span>, according to a consult by ISI Group Inc.</p>
<p> Results from a consult of 146 investors were expelled late on Tuesday by <span>Mark Schoenebaum</span>, a curative researcher for a investment investigate services group. Wall Street is energetically available formula of a trials and expects outrageous intensity sales if possibly of a medicines proves means to detain a course of a memory-robbing disease.</p>
<p> Pfizer and Lilly are coming in a third entertain to divulge a categorical commentary from vast studies of their particular medicines, <span>bapineuzumab</span> and <span>solanez...